187795-43-3 Usage
Uses
Used in Organic Synthesis:
1-(tert-butyl)-3-cyclopropyl-1H-pyrazol-5-amine is used as a building block or intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structural features, including the tert-butyl and cyclopropyl groups, provide opportunities for the development of novel chemical entities with specific properties.
Used in Pharmaceutical Industry:
1-(tert-butyl)-3-cyclopropyl-1H-pyrazol-5-amine is used as a potential active pharmaceutical ingredient (API) for the development of new drugs. Its amine functional group allows for further chemical modifications, which can enhance its pharmacological properties, such as solubility, stability, and bioavailability. 1-(tert-butyl)-3-cyclopropyl-1H-pyrazol-5-amine's potential applications in this industry may include the treatment of various diseases and disorders.
Used in Agrochemical Industry:
1-(tert-butyl)-3-cyclopropyl-1H-pyrazol-5-amine is used as a starting material or intermediate in the synthesis of agrochemicals, such as pesticides and herbicides. Its unique structural features can be exploited to develop new agrochemicals with improved efficacy, selectivity, and environmental compatibility.
Check Digit Verification of cas no
The CAS Registry Mumber 187795-43-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,7,7,9 and 5 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 187795-43:
(8*1)+(7*8)+(6*7)+(5*7)+(4*9)+(3*5)+(2*4)+(1*3)=203
203 % 10 = 3
So 187795-43-3 is a valid CAS Registry Number.
187795-43-3Relevant academic research and scientific papers
5- OR 7-AZAINDAZOLES AS BETA-LACTAMASE INHIBITORS
-
Page/Page column 41; 43; 44, (2020/09/19)
The present invention relates to β-lactamase inhibitors having the following general formula (I): wherein R1-R4 and X1-X2 are defined in the specification, pharmaceutical composition thereof, and use thereof for the treatment of a bacterial infection, alone or in combination with β-lactam antibiotics and/or other antibiotics and/or other β-lactamase inhibitors.
INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)
-
Page/Page column 159, (2010/06/15)
The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein ("FABP") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)
